Home > Insider Trading > Filing (0001209191-21-057822)

Filing Details

Accession Number:: 0001209191-21-057822
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-27 17:51:09
Reporting Period:: 2021-09-23

Accepted Time:: 2021-09-27 17:51:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1808865	Iteos Therapeutics Inc.	ITOS	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1134655	Ansbert Gadicke	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1687078	Bioimpact Capital Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1691428	L.p. Fund Impact Oncology Ubs	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1721036	L.p. Management (Cayman) Fund Impact Oncology	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-09-23	60,600	$27.96	5,458,833	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-09-23	1,200	$28.38	5,457,633	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-09-24	8,221	$27.81	5,449,412	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-09-27	19,455	$27.09	5,429,957	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
The shares were sold as follows: 21,575 by MPM BioVentures 2014, L.P. ("BV 2014"), 743 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,626 by MPM BioVentures 2018, L.P. ("BV 2018"), 269 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 24,387 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC.
BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $28.24 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,885,806 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 64,908 by AM BV2014, 1,191,035 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 23,505 by AM BV2018 and 2,131,653 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 427 by BV 2014, 15 by AM BV2014, 270 by BV 2018, 5 by AM BV2018 and 483 by UBS Oncology.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.26 to $28.46 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,885,379 by BV 2014, 107,713 by BV 2014(B), 64,893 by AM BV2014, 1,190,765 by BV 2018, 54,213 by BV 2018(B), 23,500 by AM BV2018 and 2,131,170 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 2,927 by BV 2014, 101 by AM BV2014, 1,849 by BV 2018, 36 by AM BV2018 and 3,308 by UBS Oncology.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.39 to $28.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,882,452 by BV 2014, 107,713 by BV 2014(B), 64,792 by AM BV2014, 1,188,916 by BV 2018, 54,213 by BV 2018(B), 23,464 by AM BV2018 and 2,127,862 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 6,926 by BV 2014, 238 by AM BV2014, 4,375 by BV 2018, 86 by AM BV2018 and 7,830 by UBS Oncology.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,875,526 by BV 2014, 107,713 by BV 2014(B), 64,554 by AM BV2014, 1,184,541 by BV 2018, 54,213 by BV 2018(B), 23,378 by AM BV2018 and 2,120,032 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.